Somatostatin receptor scintigraphy (SRS) for localization of neuroendocrine tumors and their metastases
HAYES, Inc.
Record ID 32006001586
English
Authors' objectives:
Somatostatin receptor scintigraphy (SRS) is a technique in which a radionuclide scan is used to find neuroendocrine and some non-neuroendocrine primary and metastatic tumors. Radioactive octreotide, a drug similar to somatostatin, is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A radiation-measuring device detects the radioactive octreotide and provides pictures showing the location of the tumor cells in the body.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=5252
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Neuroendocrine Tumors
- Radionuclide Imaging
- Receptors, Somatostatin
- Tomography, Emission-Computed
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.